Published in Health Business Week, January 12th, 2007
Hematide, a novel peptide-based drug designed to stimulate the production of red blood cells, is the company's first product candidate to enter the clinic. Hematide is being evaluated in phase II clinical trials for the treatment of anemia associated with chronic kidney disease and in anemic cancer patients undergoing chemotherapy. The data were presented in a poster session (Abstract #1290) at the 48th Annual Meeting of the American...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.